ZW439
/ Zymeworks
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
ZW439, a novel CLDN18.2-targeting pan-RAS inhibitor antibody drug conjugate for the treatment of RAS mutated pancreatic cancer
(AACR 2026)
- "In vivo, ZW439 demonstrates highly efficacious anti-tumor activity in multiple CLDN18.2 expressing xenografts and has a favourable PK profile. ZW439's pan-RASi ADC drug-linker platform demonstrates encouraging tolerability, with no significant toxicity observed following dosing up to 200 mg/kg in mice.The encouraging preclinical profile of ZW439 supports its potential as a differentiated therapeutic for the treatment of Pancreatic cancer."
ADC • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CLDN18
1 to 1
Of
1
Go to page
1